Serveur d'exploration Tocilizumab - Exploration (Accueil)

Index « MeshFr.i » - entrée « Anticorps monoclonaux humanisés »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Anticorps monoclonaux d'origine murine < Anticorps monoclonaux humanisés < Anticorps neutralisants  Facettes :

List of bibliographic references indexed by Anticorps monoclonaux humanisés

Number of relevant bibliographic references: 1800.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000003 (2020) Charlotte Girard-Guyonvarc'H ; Michele Iudici[Targeted therapies for connective tissue diseases and vasculitis].
000011 (2020) Binqing Fu ; Xiaoling Xu ; Haiming WeiWhy tocilizumab could be an effective treatment for severe COVID-19?
000012 (2020) Seoyoung C. Kim [États-Unis] ; Sebastian Schneeweiss [États-Unis]When Randomized Clinical Trials and Real-World Evidence Say the Same: Tocilizumab and Its Cardiovascular Safety.
000075 (2020) Anca D. Askanase [États-Unis] ; Leila Khalili [États-Unis] ; Jill P. Buyon [États-Unis]Thoughts on COVID-19 and autoimmune diseases
000149 (2020) Emre Bilgin [Oman] ; Rem Ozarli [Turquie] ; Levent K L Ç [Turquie] ; Ertu Rul Ça R Bölek [Turquie] ; Gözde Kübra Yard Mc [Turquie] ; Ömer Karada [Turquie]Some concerns from Turkey.
000190 (2020) Yuko Kaneko [Japon] ; Hideto Kameda [Japon] ; Kei Ikeda [Japon] ; Tomonori Ishii [Japon] ; Kosaku Murakami [Japon] ; Hyota Takamatsu [Japon] ; Yoshiya Tanaka [Japon] ; Takayuki Abe [Japon] ; Tsutomu Takeuchi [Japon]Response to: 'Some concerns from Turkey' by Bilgin et al.
000197 (2020) Angela Ceribelli [Italie] ; Francesca Motta [Italie] ; Maria De Santis [Italie] ; Aftab A. Ansari [États-Unis] ; William M. Ridgway [États-Unis] ; M. Eric Gershwin [États-Unis] ; Carlo Selmi [Italie]Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy
000245 (2020) Ana Luisa Oliveira [Portugal] ; Carina Ruano [Portugal] ; Nuno Riso [Portugal] ; José Cepeda Ribeiro [Portugal] ; Maria Francisca Moraes-Fontes [Portugal]Paradoxical pulmonary event under tocilizumab treatment for systemic sclerosis-associated usual interstitial pneumonia.
000258 (2020) Peter N. Taylor [Royaume-Uni] ; Lei Zhang [Royaume-Uni] ; Richard W J. Lee [Royaume-Uni] ; Ilaria Muller [Royaume-Uni] ; Daniel G. Ezra [Royaume-Uni] ; Colin M. Dayan [Royaume-Uni] ; George J. Kahaly [Allemagne] ; Marian Ludgate [Royaume-Uni]New insights into the pathogenesis and nonsurgical management of Graves orbitopathy.
000350 (2020) Anna-Sophia Kattner ; Ernst Holler ; Barbara Holler ; Sebastian Klobuch ; Daniela Weber ; Danilo Martinovic ; Matthias Edinger ; Wolfgang Herr ; Daniel WolffIL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis
000351 (2020) Etienne Dufranc [France] ; Arnaud Del Bello [France] ; Julie Belliere [France] ; Nassim Kamar [France] ; Stanislas Faguer [France]IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome
000355 (2020) Heidi LedfordHow does COVID-19 kill? Uncertainty is hampering doctors' ability to choose treatments.
000381 (2020) Xuhan Zhang [République populaire de Chine] ; Kaidi Song [République populaire de Chine] ; Fei Tong [République populaire de Chine] ; Mingming Fei [République populaire de Chine] ; Hui Guo [République populaire de Chine] ; Zhaohui Lu [République populaire de Chine] ; Jinquan Wang [République populaire de Chine] ; Changcheng Zheng [République populaire de Chine]First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab
000415 (2020) Tomoyuki Asano ; Shuzo Sato ; Jumpei Temmoku ; Yuya Fujita ; Makiko Yashiro Furuya ; Naoki Matsuoka ; Hiroko Kobayashi ; Eiji Suzuki [Japon] ; Hiroshi Watanabe ; Kiyoshi MigitaEffectiveness of Tocilizumab in juvenile patients with refractory Takayasu arteritis
000437 (2020) Catalina Sanchez-Alvarez [États-Unis] ; Matthew Koster [États-Unis] ; Ali Duarte-García [États-Unis] ; Kenneth J. Warrington [États-Unis]Disease progression of Takayasu arteritis in two patients treated with tocilizumab.
000494 (2020) Naoto Sakumura [Japon] ; Hitoshi Irabu [Japon] ; Natsumi Inoue [Japon] ; Mao Mizuta [Japon] ; Masaki Shimizu [Japon]Clinical usefulness of longitudinal IL-6 monitoring in a patient with Takayasu aortitis receiving tocilizumab.
000521 (2020) Jon T. Giles [États-Unis] ; Naveed Sattar [Royaume-Uni] ; Sherine Gabriel [États-Unis] ; Paul M. Ridker [États-Unis] ; Steffen Gay [Suisse] ; Charles Warne [Royaume-Uni] ; David Musselman [États-Unis] ; Laura Brockwell [Royaume-Uni] ; Emma Shittu [Royaume-Uni] ; Micki Klearman [États-Unis] ; Thomas R. Fleming [États-Unis]Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial.
000544 (2020) Carina Mihai [Suisse] ; Rucsandra Dobrota [Suisse] ; Maria Schröder [Suisse] ; Alexandru Garaiman [Suisse] ; Suzana Jordan [Suisse] ; Mike Oliver Becker [Suisse] ; Britta Maurer [Suisse] ; Oliver Distler [Suisse]COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD.
000582 (2020) Franco Maria Buonaguro [Italie] ; Igor Puzanov [États-Unis] ; Paolo Antonio Ascierto [Italie]Anti-IL6R role in treatment of COVID-19-related ARDS
000586 (2020) Tomohiro Koga ; Naoko Hagimori [Japon] ; Shuntaro Sato [Japon] ; Shinpei Morimoto [Japon] ; Naoki Hosogaya [Japon] ; Chizu Fukushima [Japon] ; Hiroshi Yamamoto [Japon] ; Atsushi KawakamiAn open-label continuation trial of tocilizumab for familial Mediterranean fever with colchicine ineffective or intolerance
000613 (2020) Bernhard Hellmich [Allemagne] ; Ana Agueda [Portugal] ; Sara Monti [Italie] ; Frank Buttgereit [Allemagne] ; Hubert De Boysson [France] ; Elisabeth Brouwer [Pays-Bas] ; Rebecca Cassie [Royaume-Uni] ; Maria C. Cid [Espagne] ; Bhaskar Dasgupta [Royaume-Uni] ; Christian Dejaco [Autriche] ; Gulen Hatemi [Turquie] ; Nicole Hollinger [Allemagne] ; Alfred Mahr [France] ; Susan P. Mollan [Royaume-Uni] ; Chetan Mukhtyar [Royaume-Uni] ; Cristina Ponte [Portugal] ; Carlo Salvarani [Italie] ; Rajappa Sivakumar [Inde] ; Xinping Tian [République populaire de Chine] ; Gunnar Tomasson [Islande] ; Carl Turesson [Suède] ; Wolfgang Schmidt [Allemagne] ; Peter M. Villiger [Suisse] ; Richard Watts [Royaume-Uni] ; Chris Young [Royaume-Uni] ; Raashid Ahmed Luqmani [Royaume-Uni]2018 Update of the EULAR recommendations for the management of large vessel vasculitis.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/MeshFr.i -k "Anticorps monoclonaux humanisés" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/MeshFr.i  \
                -Sk "Anticorps monoclonaux humanisés" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    MeshFr.i
   |clé=    Anticorps monoclonaux humanisés
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021